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Background: MTO1 and MRPL41 are nuclear-encoded mitochondrial genes encoding a mitochondrial
tRNA-modifying enzyme and a mitochondrial ribosomal protein, respectively. Although both genes have been
known to have potential roles in cancer, little is known about their molecular regulatory mechanism, particularly
from an epigenetic approach. In this study, we aimed to address their epigenetic regulation through the estrogen
receptor (ER) in breast cancer.
Methods: Digital differential display (DDD) was conducted to identify mammary gland-specific gene candidates
including MTO1 and MRPL41. Promoter CpG methylation and expression in breast cancer cell lines and tissues were
examined by methylation-specific PCR and real time RT-PCR. Effect of estradiol (E2), tamoxifen, and trichostatin A
(TSA) on gene expression was examined in ER + and ER- breast cancer cell lines. Chromatin immunoprecipitation
and luciferase reporter assay were performed to identify binding and influencing of the ER to the promoters.
Results: Examination of both cancer tissues and cell lines revealed that the two genes showed an opposite
expression pattern according to ER status; higher expression of MTO1 and MRPL41 in ER- and ER+ cancer types,
respectively, and their expression levels were inversely correlated with promoter methylation. Tamoxifen, E2, and
TSA upregulated MTO1 expression only in ER+ cells with no significant changes in ER- cells. However, these
chemicals upregulated MRPL41 expression only in ER- cells without significant changes in ER+ cells, except for
tamoxifen that induced downregulation. Chromatin immunoprecipitation and luciferase reporter assay identified
binding and influencing of the ER to the promoters and the binding profiles were differentially regulated in
ER+ and ER- cells.
Conclusions: These results indicate that different epigenetic status including promoter methylation and different
responses through the ER are involved in the differential expression of MTO1 and MRPL41 in breast cancer.
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The estrogen receptor (ER) plays key roles in breast
cancer development and progression [1,2]. Thus, key
areas of study in breast cancer are those mechanisms
that regulate ER expression in normal and malignant
breast tissues. Recent studies have shown that gene ex-
pression profiles differ according to hormone receptor
status of the breast cancer [3,4]. ER status also affects
the DNA methylation state of a wide range of genes
such as FAM124B, ST6GALNAC1, NAV1, and PER1 in
breast cancer [5]. These genetic and epigenetic alter-
ations in ER + tumors make them more sensitive to
endocrine therapy, whereas ER- tumors are hormone
independent [6,7].
MTO1 and MRPL41 are nuclear-encoded mitochondrial
genes located at 6q13 and 9p34, respectively. MTO1
encodes an enzyme involved in post-transcriptional modi-
fication of mitochondrial tRNAs (mt-tRNAs) [8]. In both
humans and yeasts, MTO1 increases the accuracy and
efficiency of mtDNA translation by catalyzing the 5-
carboxymethylaminomethylation of the wobble uridine
base in three mitochondrial tRNAs such as mt-tRNAGln,
mt-tRNAGlu, and mt-tRNALys [9]. A few potentially patho-
genic variants of MTO1 have been identified in patients
with mitochondrial disorders [10]. However, its expression
and regulatory mechanism in breast cancer has not been
determined.
MRPL41 (also known as BMRP) encodes a mitochon-
drial ribosomal protein that induces apoptosis in P53-
dependent and independent manners via BCL2 and
caspases in lymphoma [11]. Ectopic expression of
MRPL41 induces cell death in several mammalian cell
lines including primary embryonic fibroblasts of mice
and human origin, and in NIH/3T3 cells, which is coun-
teracted by BCL-2 [12,13]. The MRPL41 protein is local-
ized in the mitochondria, stabilizes the p53 protein, and
enhances its translocation to the mitochondria, thereby
inducing apoptosis. Interestingly, MRPL41 stabilizes
the p27 (Kip1) protein in the absence of p53 and arrests
the cell cycle at the G1 phase. These results suggest
that MRPL41 plays an important role in p53-induced
mitochondrion-dependent apoptosis and that MRPL41
exerts a tumor-suppressive effect in association with p53
and p27. MRPL41 is downregulated in breast and kidney
cancer cell lines and in tissues supporting its role as a
tumor-suppressor [14].
Although MTO1 and MRPL41 have potential roles in
human diseases, little is known about their molecular
mechanism, particularly from an epigenetic approach.
In this study, we examined the regulation of MTO1 and
MRPL41 in ER+ and ER- breast cancer cells, and also
in cells treated with estradiol (E2) and tamoxifen. We
further investigated whether their regulation involved
an epigenetic mechanism. Our present data show thatmethylation was inversely correlated with the differential
expression. Moreover, the histone deacetylase inhibitor
trichostatin A (TSA) increased MTO1 and MRPL41 ex-
pression in ER- and ER+ breast cancer cells, respectively.
We found that ER differentially bound to the half-
estrogen responsive elements at the promoter of both
genes in ER+ and ER- cells.
Methods
In silico mining of breast cancer-specific genes
Digital differential display (DDD) was conducted (http://
www.ncbi.nlm.nih.gov/UniGene/ddd.cgi) to identify mam-
mary gland-specific gene candidates. We compared ex-
pressed sequence tag (EST) libraries from human breast
tissues and those from various other somatic tissues. Of
the genes that were overrepresented in breast tissue-
derived libraries, ESTs of which the epigenetic regulatory
mechanism has not yet been addressed were selected for
further analysis.
Study subjects
All patients provided written informed consent to do-
nate removed tissue to the National Cancer Center
(NCC) in Korea and samples were obtained according to
protocols approved by the Research Ethics Board of
NCC. Forty-eight pairs of breast cancers (BrCa) and
their corresponding adjacent normal tissue specimens
were obtained from patients who had undergone surgery
between 2010 and 2011 at NCC. BrCa specimens were
subjected to histological examination by an expert path-
ologist for independent confirmation of ER expression
grade. The ER expression grades were scored by the
Allred scoring system and varied between specimens,
with a composite score ranging from 0 to 7. The average
ER expression grade of the specimens with reported
scores was 4.1. Specimens showing an ER expression
grade > 3 were considered ER+. As chemo- and radio-
therapy have previously been implicated in altering
methylation patterns, no subjects who had received
either type of treatment were included in the study.
Cell culture and treatment of chemicals
The breast cancer cell lines MCF7 (ER+), T47D (ER+),
MDA-MB-231 (ER-), and BT-549 (ER-) were purchased
from the American Type Culture Collection (Manassas,
VA, USA) and grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum. 5-
Aza-2’-deoxycytidine (Sigma, St. Louis MO, USA), a
methyltransferase inhibitor, was added to the culture
medium at 5 μM for 72 hr to induce demethylation of
the cytosine residues, and the medium was changed
every 24 hr. E2 (Sigma) and tamoxifen (Sigma) were
treated at final concentrations of 1 nM and 1 μM for
24 hr, respectively.
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To isolate chromosomal DNA from breast tissue, approxi-
mately 50–100 mg of tissue was extracted using a genomic
DNA purification kit (Promega, Madison, WI, USA) ac-
cording to the manufacturer’s protocol. The extracted DNA
was eluted with 250 μl of distilled water. Total RNA from
breast tissue was prepared using Trizol according to the
manufacturer’s protocols (Gibco BRL, Carlsbad, CA, USA).
Genomic DNA and total RNA from cultured cells were
prepared using an AllPrep DNA/RNA Mini kit (Qiagen,
Valencia, CA, USA) with elution of 100 and 30 μl, respectively.
Methylation-specific polymerase chain reaction (PCR) and
bisulfite sequencing
Sodium bisulfite modification of genomic DNA was car-
ried out using an EpiTect Bisulfite kit (Qiagen) according
to the manufacturer’s protocol using 0.1 mg of purified
DNA. The design of the MTO1 and MRPL41 PCR
primers (Additional file 1: Table S1) and quantitative PCR
were carried out as described previously [15]. Briefly, pri-
mer sequences were designed using the Methprimer pro-
gram (http://www.urogene.org/methprimer/index1.html).
Quantitative PCR was performed using a Power SYBR
Green Kit (Applied Biosystems, Foster City, CA, USA) ac-
cording to the manufacturer’s protocol. A methylation
index was calculated for each sample using the following
formula: methylation index = 1 / [1 + 2−(CTu − CTme)] ×
100%, where CTu is the average cycle threshold (CT) ob-
tained from duplicate quantitative PCR analyses using the
unmethylated primer pair, and CTme is the average CT
obtained using the methylated primer pair.
For sequencing of the methylated sites, the bisulfite-
treated DNA was subjected to PCR to amplify the region.
The primer sequences used were listed in Additional file 1:
Figure S1. The PCR conditions were 94°C for 2 min,
followed by 30 cycles of 94°C for 20 s, 55°C for 20 s and
72°C for 30 s, with a final extension at 72°C for 5 min. The
resulting products were purified using a Qiaex II gel ex-
traction kit (Qiagen) and then subjected to direct sequen-
cing in both direction. The methylation ratio of each CpG
site for each tissue was calculated as the percentage of
methylation versus the methylated plus unmethylated sites.
Quantitative real-time reverse transcription (RT)-PCR
analysis
MTO1 and MRPL41 expression levels were measured by
quantitative real-time RT-PCR analysis using cDNA syn-
thesized from 5 μg of total RNA and a reverse transcrip-
tion kit (Toyobo, Osaka, Japan). One microliter of cDNA
was used for the PCR, and duplicate reactions were per-
formed for each sample using a Kapa SYBR Fast qPCR Kit
(Kapa Biosystems, Woburn, MA, USA) with gene-specific
primers on an ABI 7500 instrument (Applied Biosystems).
The primers used for these selected genes are listed inAdditional file 1: Figure S1. RNA quantity was normalized
to GAPDH content, and gene expression was quantified
according to the 2-ΔCt method [15].
Chromatin immunoprecipitation-PCR (ChIP-PCR)
ChIP assays were performed using an EZ ChIP Chromatin
Immunoprecipitation kit (Millipore, Billerica, MA, USA)
as described in the supplier’s protocol. Briefly, the cross-
linked chromatin was sonicated after cell lysis and then
incubated with antibodies against ER (Millipore) at 4°C
overnight. The immunocomplex was precipitated with
Protein A-agarose (Millipore), and the beads were washed,
sequentially treated with 10 μl of RNase A (37°C for 30 min)
and 75 μl of Proteinase K (45°C for 4 h), and incubated at
65°C overnight to reverse cross-link the chromatin. The
DNA was recovered by phenol-chloroform extraction and
coprecipitation with glycogen, and dissolved in 50 μl of
Tris-EDTA (TE) buffer. DNA associated with the ER was
amplified by PCR using 1 μl of the precipitated DNA. PCR
primers (sequences are in Additional file 1: Figure S1) were
designed to amplify the ER-responsive elements (EREs) at
the promoter. The PCR conditions were 30 cycles at 94°C
for 40 s, 57°C for 1 min, and 72°C for 40 s.
Luciferase assay
The upstream region of MTO1 and MRPL41 was ampli-
fied by PCR from human chromosomal DNA and cloned
into the MluI and HindIII sites of pGL2Basic luciferase
vector (Promega). The PCR was performed using primers
(Additional file 1: Figure S1) with 35 cycles at 94°C for 30
seconds, 55°C for 1 minute, then 72°C for 2 minutes. 100
ng of the recombinant luciferase expression vector was
transiently transfected into 1 × 104 cells in 96-well culture
plates using a transfection kit (Qiagen). Luciferase activity
was measured 36 hours after transfection in three inde-
pendent cultures using a dual-luciferase reporter assay
system kit (Promega) on a Molecular Devices Filter Max
F3 (Sunnyvale, CA, USA). The activity from the promoter
spanning R0 ~ R4 of MTO1 and R0 ~ R6 of MRPL41 was
normalized with that from the promoter containing only
R0 fragment of each gene.
Statistical analysis
Student’s t-test was used to detect differences in the
methylation and expression level between normal and
cancerous tissues and between ER+ and ER- tissues using
SPSS for Windows, release 17.0 (SPSS Inc., Chicago, IL,
USA). P-values < 0.05 were considered significant.
Results
MTO1 and MRPL41 show opposite methylation
and expression in ER + and ER- breast cells
DDD was conducted to identify genes that are abnormally
expressed in breast cancer, and MTO1 and MRPL41 were
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with upregulation in cancer tissue (Additional file 2:
Table S2). To confirm upregulation in cancer, MTO1
and MRPL41 expression was examined by real-time
RT-PCR in breast cancer tissues and nearby normal tis-
sues. However, the results revealed no statistically sig-
nificant expression difference between cancer tissues
and normal tissues for both MTO1 and MRPL41. In-
stead, expression differences emerged according to the ER
status of the cancer tissues (Figure 1 and Additional file 3:
Figure S1). Interestingly, the two genes showed an oppos-
ite pattern with MTO1 showing downregulation (p < 0.01)
and MRPL41 showing upregulation (p < 0.05) in ER +
tissues compared to ER- tissues. These results led us to
explore the molecular mechanism underlying this differ-
ential expression based on ER status.
We focused on the epigenetic mechanism including
DNA methylation and histone modification at the pro-
moter. First, CpG methylation at the promoter was
examined for ER+ and ER- cancer tissues by methylation-
specific PCR. As shown in Figure 1, methylation level was
inversely correlated with expression level; MTO1 showed
higher CpG methylation but lower expression in ER + can-
cer tissues than in the ER- cancer tissues. MRPL41 showedFigure 1 Opposite methylation and expression patterns of
MTO1 vs. MRPL41 according to estrogen receptor (ER) status in
breast cancer tissues. Methylation and expression of MTO1 (A and
C) and MRPL41 (B and D) were examined by real-time methylation-
specific polymerase chain reaction (PCR) and RT-PCR, respectively, in
ER(+) and ER(-) breast cancer tissues. Numbers in parentheses
denote the number of examined tissues. Each sample was examined
in duplicate, and the average was applied to the plot. Data for
individual patients is shown in Additional file 3: Figure S1.lower CpG methylation but higher expression in ER + can-
cer tissues than in ER- cancer tissues.
Next, the opposite expression patterns and methylation
relationships were further examined in ER+ and ER-
breast cancer cell lines. The results indicated that the ex-
pression and methylation profiles in the cancer cell lines
were the same as those in cancer tissues, although the
overall methylation level between the cells and tissues was
different (Figure 2). Further examination of the CpG sites
by bisulfite sequencing confirmed the opposite methyla-
tion profile of the two genes in the ER+ and ER- cells
(Additional file 4: Figure S2A and B). However, unrelated
genes, A1BG and ETAA1 in the Additional file 2: Table S2,
which appeared downregulated in breast cancer showed no
methylation difference according to ER status as shown
in the Additional file 4: Figure S2C. Therefore, MTO1 and
MRPL41 were regulated by methylation in opposite man-
ners depending on ER status.
To address the effect of promoter methylation on gene
expression, the methyltransferase inhibitor 5-Aza-dC
was added to the cancer cell lines, and methylation
and expression levels were monitored by methylation-
specific PCR and RT-PCR, respectively. 5-Aza-dC
induced demethylation of the two genes in cells, particu-
larly in ER+ or ER- cells that showed higher methylationFigure 2 Opposite methylation and expression patterns of
MTO1 vs. MRPL41 according to estrogen receptor (ER) status in
breast cancer cell lines. Methylation and expression of MTO1 (A
and C) and MRPL41 (B and D) were examined by real-time
methylation-specific polymerase chain reaction (PCR) and RT-PCR,
respectively, in ER(+) and ER(-) breast cancer cell lines. Each sample
was examined in three independent reactions, and the average
relative level is presented with the standard error.
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pression levels increased in drug-treated cells regardless
of cell type. This result suggests that differential pro-
moter methylation contributes, at least in part, to the
opposite regulation of MTO1 and MRPL41.
MTO1 and MRPL41 are oppositely regulated by E2,
tamoxifen, and trichostatin A
As MTO1 and MRPL41 showed opposite expression
patterns depending on ER status, we further examined
the role of ER on their expression by monitoring the
effect of an ER agonist and an antagonist. The agonist
E2 increased MTO1 expression 3.9 and 7.4-fold in
ER+MCF7 and T47D cells, respectively, whereas it
slightly decreased in ER- MDAMB231 and BT549 cells
(Figure 4A). E2 increased MRPL41 gene expression 3.7
and 1.2-fold in ER- MDAMB231 and BT549 cells,
whereas it induced a slight change with a 1.3-fold de-
crease and a 1.1-fold increase in ER+MCF7 and T47D
cells, respectively (Figure 4D).
The antagonist tamoxifen increased MTO1 expression 2
and 15-fold in ER+ cells, whereas it increased MRPL41 ex-
pression 3.2 and 1.1-fold in ER- cells (Figure 4B and E).
However expression of the two genes in other ER cell typeFigure 3 5-Aza-dC induced upregulation of MTO1 and MRPL41.
Cultured breast cancer cells were treated with 5-Aza-dC, and
methylation and expression levels were examined for MTO1 (A and
C) and MRPL41 (B and D) by real-time methylation-specific
polymerase chain reaction (PCR) and RT-PCR, respectively. Estrogen
receptor (ER) status of each cell line is indicated as (+) or (-). Gray
and black bars represent before and after treatment with 5-Aza-dC,
respectively. Each sample was examined in three independent
reactions, and the average relative level is presented with the
standard error.decreased in all cases, except MTO1 was increased slightly
in BT549 cells.
The histone deacetylase inhibitor TSA was added to
the cultured cells to induce histone acetylation and to
examine the effect of chromatin structure on gene ex-
pression. Interestingly, TSA also induced the same pat-
tern of expression change for the two genes in ER+ and
ER- cells. MTO1 was increased 3.6 and 5-fold in ER+
cells, whereas MRPL41 was increased 1.9 and 2-fold in
ER- cells (Figure 4C and F). Expression in the other cell
types only decreased slightly.
Taken together, E2, tamoxifen, and TSA induced up-
regulation of MTO1 in ER+ cells while inducing upregu-
lation of MRPL41 in ER- cells. The effect of the three
chemicals in the other ER type cells was not remarkable,
except for a slight downregulation.
MTO1 and MRPL41 promoters are differentially regulated
in ER+ and ER- cells
We speculated that differential ER binding to the ER-
responsive element (ERE) at the promoter could be a
candidate molecular mechanism underlying the differen-
tial regulation of MTO1 and MRPL41 in ER+ and ER-
cells. Thus, we first searched for EREs at the promoters
of the two genes. As shown in Figure 5A, MTO1 had
four groups of ERE-related sequences scattered over 1
kb upstream of the transcription start site with 1–3 re-
peats in each group. The perfect consensus sequence of
ERE is GGTCAnnnTGACC, however, all EREs in MTO1
strikingly appeared as perfect or imperfect half-ERE
(hERE) rather than a full ERE such as GGTCA, TGACC,
GGCCA, and GGCAC. It has been known that the
hERE is properly recognized by the ER [16].
ChIP analysis of the MTO1 promoter determined that
among the R1–R4 hEREs, only R3 and R4 were bound to
ER-α in ER+ MCF7 cells (Figure 5B). However, R1 and R2
were also bound to ER-α as well as R3 and R4 in ER-
MDAMB231 cells (Figure 5C). These differences in ER
binding profiles may partly explain the opposite expres-
sion pattern between ER+ and ER- cells. There did not ap-
pear to be any considerable effect of E2 on the ER binding
of both cell types. MRPL41 had six groups (R1–R6 in
Figure 6A) of hEREs scattered within 1 kb of the promoter
region with 2–8 repeats. Their sequences appeared as
GGGCA, TGACC, or GGTGG. ChIP analysis of the
PRPL41 promoter that had driven higher expression in
ER- cells generally showed less ER binding compared
to that of MTO1. Only R1 showed a remarkable level
of binding in the ER+ MCF7 cells (Figure 6B), whereas
R2 and R4 additionally bound in ER- MDAMB231 cells
(Figure 6C). When E2 was added to the culture, new bind-
ing to R6 emerged in both cell types.
To further analyze the effect of hEREs on the differen-
tial regulation of MTO1 and MRPL41 in ER+ and ER-
Figure 4 Opposite effect of estradiol (E2), tamoxifen (TAM), and trichostatin A (TSA) on MTO1 vs. MRPL41 according to estrogen
receptor (ER) status in breast cancer cell lines. Cultured cells were treated with E2, TAM, and TSA, and MTO1 (A–C) and MRPL41
(D–F) expression levels were examined by real-time reverse transcription polymerase chain reaction. Gray and black bars represent before
and after treatment with the indicated chemical. Each sample was examined in three independent reactions, and the average relative level is
presented with the standard error.
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measured using a luciferase reporter gene in MCF7 and
MDAMB231 cells cultured with or without E2. When
the cells were treated with E2, the MTO1 promoter con-
taining the R1 ~ R4 regions significantly increased the re-
porter activity in the MCF7 cell, meanwhile the MRPL41
promoter containing the R1 ~ R6 regions significantly
increased the reporter activity in the MDAMB231 cellFigure 5 Chromatin immunoprecipitation (ChIP) analysis of the MTO1
performed on the MTO1 promoter using anti-ER-α antibody followed by p
element (1/2ERE) containing sub-regions. (A) Schematic diagram of the MT
(R1-R4). The number of triangles denotes a tandem repeat of the 1/2ERE. P
(B and C) Results of ChIP-PCR for the ER+ MCF7 cells (B) and the ER- MDA(Figure 7). These results support the fact that the two
genes are upregulated by E2 in the opposite ER cell types
as indicated in Figure 4.
Discussion
Promoter methylation and histone modification of cancer-
related genes have played essential roles during carcino-
genesis [17-20]. Recent data suggest that epigenetic statuspromoter against estrogen receptor (ER)-α. ChIP assays were
olymerase chain reaction (PCR) to amplify the half-ER-responsive
O1 promoter showing the four ER-responsive element (ERE) groups
lausible binding sites for other transcriptional factors are also indicated.
MB231 cell (C). Cells were not treated (-) or treated (+) with estradiol.
Figure 6 Chromatin immunoprecipitation (ChIP) analysis of the MRPL41 promoter against estrogen receptor (ER)-α. ChIP assays were
performed on the MRPL41 promoter using anti-ER-α antibody followed by polymerase chain reaction (PCR) to amplify the half-ER-responsive
element containing sub-regions. (A) Schematic diagram of the MRPL41 promoter showing the six ER-responsive element (ERE) groups (R1–R6).
The number of triangles denotes tandem repeat of the 1/2ERE. Plausible binding sites for other transcriptional factors are also indicated. (B and C)
Results of ChIP-PCR for ER+MCF7 cells (B) and ER- MDAMB231 cells (C). Cells were not treated (-) or treated (+) with estradiol.
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tion of estrogens and could also be affected by ER status
[21,22]. The present results indicate that the two mito-
chondrial genes, MTO1 and MRPL41, were differentially
regulated in breast cancer such that they showed the op-
posite response to E2, tamoxifen, and TSA. Our findings
suggest that the opposite pattern of promoter methylation
and differential binding of the ER to the promoter in both
genes are explanations for this phenomenon.Figure 7 Opposite activation of MTO1 and MRPL41 promoter
by E2 in ER+ and ER- breast cancer cells. Upstream regions of
MTO1 (from -994 to +18) (A) and MRPL41 (from -1,030 to +1)
(B) were placed upstream of the luciferase gene, and luciferase
activities were determined from transiently transfected ER+ (MCF7)
and ER- (MDAMB231) cells. Cells were not treated (gray bar) or
treated (black bar) with estradiol (E2). Each experiment was
performed at least three times and the data are presented as the
average and standard error after normalization with activity from
vectors containing R0 region in each gene.In previous studies, a group of genes was regulated by
the ER, and the majority of them were upregulated in re-
sponse to estrogens whereas only a few genes including
NFκB and CXCR7 were downregulated in response to es-
trogens [23,24]. However, no nuclear-encoded mitochon-
drial genes are known in terms of estrogen response, and
this is the first study that has reported epigenetic regula-
tion of mitochondrial genes in breast cancer according to
ER status. Surprisingly, MRPL41 was upregulated by E2 in
the MDAMB231 cell that was ER negative. It has been
known that alternative signaling pathways were activated
in ER- cancer cells. For example, estrogen is able to trigger
signaling through receptors other than ER such as GPR30,
upregulating target genes like c-fos [25]. Related with this
fact, it is speculated that MRPL41 could be upregulated by
alternative receptors other than ER.
The ER antagonist tamoxifen also stimulated expression
of MTO1 in ER+ cells similar to E2 and TSA. This
estrogen-like stimulatory effect of tamoxifen has also been
found in several other genes such as Heparinase and
PTPRO [26,27], providing an explanation for altered tam-
oxifen activity from an antagonist to an agonist. This re-
sult suggests that tamoxifen acts as an MTO1 agonist in
ER+ cells, but as an MRPL41 antagonist in ER- cells. De-
tailed understanding of the mechanism through which
estrogen and tamoxifen affect MTO1 and MRPL41 tran-
scription is expected to provide new insights into breast
cancer progression and suggest new strategies for delaying
or reversing this process.
It is thought that upregulation of MTO1 by TSA in
ER+ cells may be linked to promoter demethylation.
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hypermethylation induces demethylation of promoters
and thereby upregulates gene expression [28,29]. We also
found that TSA induced demethylation in the ER+ cells
which had shown hypermethylation and downregulation
of MTO1 (Additional file 5: Figure S3). Therefore, histone
acetyl transferase (or deacetylase) and CpG methyltrans-
ferase may act together to regulate gene expression on the
MTO1 promoter in the ER+ cells.
In this study, the hERE sites scattered at the MTO1 and
MRPL41 promoters appropriately bound the ER. The two
genes responded differently according to ER status in both
breast tissues and cultured cells. However, they did not
show any significant changes in response to E2, suggesting
that other elements are required for the complete regula-
tion of ER binding. In fact, similar to other E2 responsive
genes expressed in human breast cancer cells such as
cathepsin D, c-fos, and c-myc [30-32], the MRPL41 up-
stream promoter region has two Sp1/Sp3 binding site near
hERE sites and five tandem repeats just downstream of
the R1 region. Two c-myc sites, instead of Sp1 sites, are
nested in hERE sites in MTO1. Previous studies suggested
that E2 stimulation results in the recruitment of the
transcription factors ERα, Sp1, and Sp3 to the promoter
[33-35]. However, further examination should be carried
out to elucidate the precise mechanism of how each hERE
acts to stimulate the two genes because our results show
that the hEREs used a different platform of transcriptional
factor recognition elements, and were differentially regu-
lated according to ER status.
It should be mentioned that the upregulated pattern of
the two genes in breast cancer shown by DDD was not re-
peated in our patient tissues. It is speculated that the EST
hits registered at the database were too small to show
statistical significance or that the ESTs were largely ex-
tracted from cancer tissues. In addition, even though there
appeared to be a significant difference, both normal and
cancer tissues generally showed lower methylation levels
when examined by methylation-specific PCR. One explan-
ation could be due to a mix-up of normal cells with cancer
cells during surgery. In fact the cancer cell lines showed
much higher methylation level than the cancer tissues.
Otherwise, other CpGs with higher methylation might be
missed because methylation-specific PCR compared only
four CpG sites. A detailed understanding of the molecular
events occurring along opposite pathways will provide
more comprehensive insight into the biology of estrogen-
driven breast tumorigenesis in the case of mitochondrial
genes and may have important implications for recom-
mendations on treatment and risk-reduction strategies.
Conclusions
In conclusion, nuclear-encoded mitochondrial MTO1
and MRPL41 showed an opposite expression patternaccording to estrogen receptor (ER) status. MTO1 was
upregulated in ER- cancer types, meanwhile MRPL41 was
upregulated in ER+ cancer types, showing an inverse cor-
relation between expression and promoter methylation.
Furthermore, modifiers of ER (E2 and tamoxifen) and
histone deacetylase (TSA) also induced the two genes in an
opposite mode in the ER+ and ER- cell types. Differential
binding and influencing of ER to the promoter is involved
in the differential regulation. Taken together, identifying the
link between epigenetic regulation and MTO1 and MTRL41
expression may represent novel breast cancer markers
that are regulated in opposite ways by ER modulators.Additional files
Additional file 1: Table S1. Sequences of primers employed in
this study.
Additional file 2: Table S2. Top 10 genes with highest enrichment in
breast identified by EST profile.
Additional file 3: Figure S1. Methylation and expression of MTO1 and
MRPL41 in breast cancer tissues according to the ER status. Methylation
and expression of MTO1 (A and B) and MRPL41 (C and D) were
examined by real-time MSP and RT-PCR, respectively in ER(+) and ER(-)
breast cancer tissues. N in parenthesis denotes the number of examined
tissues. Each sample was examined in duplicate and the average was
applied to the plot.
Additional file 4: Figure S2. Methylation status of CpG islands at the
promoter of MTO1 and MRPL41 in breast cancer cell lines. Schematic
diagram of the promoter is presented with the CpG region of which
methylation status was determined by MSP and bisulfite sequencing.
CpG sites were denoted by vertical lines in red at the top. Methylation
status determined by direct sequencing was denoted by circles.
Sequencing diagrams corresponding to different methylation levels are
presented at the bottom. (A) MTO1. (B) MRPL41. (C) A1BG and ETAA1.
Additional file 5: Figure S3. Change of methylation level of MTO1 and
MRPL41 according to the ER status after TSA treatment. Methylation of
MTO1 (A) and MRPL41 (B) were examined by real-time MSP in ER(+) and
ER(-) breast cancer cell lines after treatment of TSA. Each sample was
examined in three independent reactions, and the average level was
presented with the standard error.Abbreviations
CpG: Cytosine guanine dinucleotide; DDD: Digital differential display;
ER: Estrogen receptor; ERE: Estrogen-responsive element; MSP: Methylation
specific PCR; RT-PCR: Reverse transcription-polymerase chain reaction.
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